EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors

R Wang, V Baxi, Z Li, D Locke, C Hedvat, Y Sun, A M Walsh, X Shao, T Basavanhally, D M Greenawalt, P Patah, R Novosiadly

ESMO Open · 2023

DOI: 10.1016/j.esmoop.2023.100784 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESMO Open, 2023. Verfasst von R Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine, Bristol Myers Squibb, Lawrenceville, USA. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The success of immune checkpoint inhibitors has revolutionized cancer treatment options and triggered development of new complementary immunotherapeutic strategies, including T-cell co-stimulatory molecules, such as glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 is a fully agonistic human immunoglobulin G subclass 1 monoclonal antibody targeting GITR. We recently presented the clinical data for BMS-986156 with or without nivolumab, which demonstrated no compelling evidence of clinical activity in patients with advanced solid tumors. Here, we further report the pharmacodynamic (PD) biomarker data from this open-label, first-in-human, phase I/IIa study of BMS-986156 ± nivolumab in patients with advanced solid tumors (NCT02598960). MATERIALS AND METHODS: We analyzed PD changes of circulating immune cell subsets and cytokines in peripheral blood or serum samples collected from a dataset of 292 patients with solid tumors before and during treatment with BMS-986156 ± nivolumab. PD changes in the tumor immune microenvironment were measured by immunohistochemistry and a targeted gene expression panel. RESULTS: BMS-986156 + nivolumab induced a significant increase in peripheral T-cell and natural killer (NK) cell proliferation and activation, accompanied by production of proinflammatory cytokines. However, no significant changes in expression of CD8A, programmed death-ligand 1, tumor necrosis factor receptor superfamily members, or key genes linked with functional parameters of T and NK cells were observed in tumor tissue upon treatment with BMS-986156. CONCLUSIONS: Despite the robust evidence of peripheral PD activity of BMS-986156, with or without nivolumab, limited evidence of T- or NK cell activation in the tumor microenvironment was observed. The data therefore explain, at least in part, the lack of clinical activity of BMS-986156 with or without nivolumab in unselected populations of cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsHumansNivolumabGlucocorticoidsAntibodies, MonoclonalCytokinesReceptors, Tumor Necrosis FactorTumor Microenvironment

Stichwörter der Autor:innen

BMS-986156biomarkerglucocorticoid-induced tumor necrosis factor receptor–related protein (GITR)immune checkpoint inhibitornivolumabpharmacodynamics

Substanzen

NivolumabGlucocorticoidsAntibodies, MonoclonalAntineoplastic AgentsCytokinesReceptors, Tumor Necrosis Factor

Autor:innen und Institutionen

  • Translational Medicine, Bristol Myers Squibb, Lawrenceville, USA.
  • Informatics & Predictive Sciences, Bristol Myers Squibb, Lawrenceville, USA.
  • Lead Discovery and Optimization, Bristol Myers Squibb, Lawrenceville, USA.
  • Global Clinical Research, Bristol Myers Squibb, Lawrenceville, USA.
  • Translational Medicine, Bristol Myers Squibb, Lawrenceville, USA. Electronic address: ruslan.novosiadly@bms.com.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Wang, R., Baxi, V., Li, Z., Locke, D., Hedvat, C., Sun, Y., Walsh, A. M., Shao, X., Basavanhally, T., Greenawalt, D. M., Patah, P., & Novosiadly, R. (2023). Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors. ESMO Open. https://doi.org/10.1016/j.esmoop.2023.100784

Vancouver

Wang R, Baxi V, Li Z, Locke D, Hedvat C, Sun Y, et al. Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors. ESMO Open. 2023. doi:10.1016/j.esmoop.2023.100784

BibTeX
@article{Wang2023,
  author = {Wang, R and Baxi, V and Li, Z and Locke, D and Hedvat, C and Sun, Y and Walsh, A M and Shao, X and Basavanhally, T and Greenawalt, D M and Patah, P and Novosiadly, R},
  title = {Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors},
  journal = {ESMO Open},
  year = {2023},
  doi = {10.1016/j.esmoop.2023.100784}
}
Kostenlos starten →